Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Together: GSK3228836 plus pegylated interferon alfa-2a in chronic hepatitis B
jRCT2041200101Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Sustained virologic response (SVR) at 24 weeks after end of treatment. Started Mar 2021; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2041200101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200101.